In September 2017, on the basis of results from 3 clinical trials (ALFA-0701,48 AML-19,49 and MyloFrance-150), the FDA reapproved GO for patients newly diagnosed with CD33-positive ALL and for patients 2 years and older with relapsed or refractory CD33-positive AML. The gene discussed is CD33; the disease is acute myeloid leukemia.